KEYMED BIO-B (02162) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 716 million yuan, representing a 67% increase compared to the previous year. However, the loss attributable to owners of the parent company expanded by 1.44% year-on-year to 523 million yuan. The basic loss per share was 1.91 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.